Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioHarvest Sciences Inc. (NASDAQ: BHST) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. BioHarvest files reports with the U.S. Securities and Exchange Commission that document its Botanical Synthesis biotechnology business, financial condition, and capital markets activity.
BioHarvest uses Form 6-K to furnish current reports, including unaudited interim condensed consolidated financial statements, management’s discussion and analysis for specific periods, material change reports, and news releases. These filings cover topics such as revenue trends from the VINIA nutraceutical brand, the growth of the CDMO Services division, and updates on technology initiatives like plant-based exosomes and saffron-derived compounds developed with partners.
The company also references its annual reporting on Form 40-F and a shelf registration statement on Form F-3, which supports public offerings of common stock. Related prospectus supplements and underwriting agreements are incorporated into 6-K submissions, providing detail on how BioHarvest raises capital to fund manufacturing expansion, research and development, marketing, and general corporate purposes.
On Stock Titan, AI-powered tools can help interpret BioHarvest’s filings by summarizing key points from lengthy financial statements and management discussions, highlighting items such as segment performance, non-IFRS measures like Adjusted EBITDA, and material changes reported to regulators. Users can also track ongoing 6-K submissions to follow new grants, strategic CDMO contracts, and other disclosed events that shape the company’s Botanical Synthesis and nutraceutical strategy.
BioHarvest Sciences Inc. (BHST) has filed a Form S-8 registering securities that may be issued under its 2025 Equity Incentive Plan. The company is a Canadian non-accelerated filer, smaller reporting registrant and emerging-growth company. O’Neill Law LLP is named as agent for service. Documents incorporated by reference include the FY-2024 Form 40-F, various Form 6-Ks and the Form 8-A describing BHST’s common shares. Exhibits comprise the legal opinion, auditor consent, the plan document, powers of attorney and the filing-fee table.
The statement contains customary indemnification provisions for directors and officers under British Columbia’s Business Corporations Act and standard undertakings to update or withdraw unsold shares. The filing was signed on 22 July 2025 by CEO Ilan Sobel, CFO Bar Dichter and the full board, with a U.S. representative signing in Nevada.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
